Most importantly, FBXW7 suppresses inflammatory signaling via decreasing C/EBPδ and its target gene TLR4 (Balamurugan et al., 2013), and FBXW7 inhibits hepatic inflammation and insulin resistance by repressing HMGB1‐mediated innate immune pathway in nonalcoholic fatty liver disease (C. Zhang et al., 2019), implying that FBXW7 might act as a suppressor of septic liver injury. Here, CEBPD is linked to metabolic dysfunction-associated steatotic liver disease.